According to a recent analysis, the global in-situ hybridization market size was valued at USD 905.3 Million in 2020 and is expected to reach USD 1,556.6 Million in terms of revenue, at a CAGR of 7.1%, through 2028. The market growth is driven by increasing prevalence of cancer, genetic disorders, infectious diseases, and associated demand for effective diagnostics techniques.
According to the statistics published by CDC in 2019, cancer was the second leading cause of death in the United States with 599,601 cancer deaths. The increasing prevalence of cancer is fuelling the need for developing more effective treatment techniques for detection of infected cells. Rise in R&D activities to diagnose cancer and other infectious diseases is projected to boost in-situ hybridization industry growth. Moreover, growing number of diagnostic centers for cancer across the globe will further provide impetus to the in-situ hybridization market expansion in the upcoming years.
Grab Your Free Sample PDF Copy Now
Key Highlights from the Report
- Based on technology, the FISH (fluorescence in-situ hybridization) segment is forecast to make major revenue contribution to the global in-situ hybridization market share over 2021-2028. The robust segmental growth can be attributed to the rising application scope of FISH technology for defected chromosome identification, drug tracking, and unusual genetic conditions.
- Based on application, the cancer diagnostic segment is projected to exhibit fastest growth rate through 2028 on account of surging demand for FISH technology for early detection of cancer cells and avert potential malignancies.
- Based on product type, the kits & reagents segment is forecast to observe notable growth over the analysis period owing to increasing need demand for various kits to perform hybridization, pre-hybridization, and post-hybridization, treatment.
- In the regional landscape, North America is forecast to account for a major chunk of the global In-Situ hybridization market share through 2028 on account of increasing rising investment in biomedical R&D activities and advancements in health infrastructure across the region. Also, increasing number of research institutions and clinical laboratories in the United States will further boost regional industry growth.
- Key players operating in the global In-Situ hybridization market include Biocare Medical, Agilent Technologies, Thermo Fisher Scientific, Abbott Laboratories, Hoffmann-La Roche Ltd.,Merck KGAa, Abnova Corporation, Bio SB, BioGenex Laboratories, and Danaher Corporation, among others.
For the purpose of this study, Emergen Research has segmented the global in-situ hybridization market on the basis of technology, application, product type, end-use, and region:
- Technology Outlook (Revenue, USD Million; 2018–2028)
- Fluorescence In-Situ Hybridization (FISH)
- Chromogenic In-Situ Hybridization (CISH)
- Application Outlook (Revenue, USD Million; 2018–2028)
- Cancer Diagnostic
- Infectious Disease
- Immunology
- Neuroscience
- Cytology
- Others
- Product Type Outlook (Revenue, USD Million; 2018–2028)
- Kits & Reagents
- Probes
- Instruments
- Software
- Others
- End-use Outlook (Revenue, USD Million; 2018–2028)
- Diagnostics Laboratories and Hospitals
- Pharmaceutical & Bio-technology
- Academic & Research Institute
- Contract Research Organizations (CRO)
- Regional Outlook (Revenue, USD Million; 2018–2028)
- North America
- S.
- Canada
- Mexico
- Europe
- Germany
- K.
- France
- Italy
- Spain
- BENELUX
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Turkey
- Rest of MEA
- North America
To get leading market solutions, visit the link below: https://www.emergenresearch.com/industry-report/in-situ-hybridization-market